Status:
RECRUITING
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
Lead Sponsor:
University of Rome Tor Vergata
Conditions:
Kidney Transplant; Complications
Liver Transplant; Complications
Eligibility:
All Genders
18-70 years
Brief Summary
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for r...
Detailed Description
Despite long-term outcomes of kidney and liver transplantation significantly improved in the last decades, high morbidity and mortality is still an issue at short term after transplantation. Specifica...
Eligibility Criteria
Inclusion
- Kidney transplant recipient at our Institution
- Liver transplant recipient at our Institution
Exclusion
- Re-transplantation
- Dual kidney transplantation
- Combined transplant (kidney-liver, kidney-pancreas)
- Autoimmune disease as indication to transplant
Key Trial Info
Start Date :
December 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06130046
Start Date
December 1 2022
End Date
December 1 2026
Last Update
August 1 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Rome Tor Vergata
Rome, Italy, 00133